USPTO serial 79221610
KHPG
Reviewed by CopyMark Law Group
Reg. 5603711Status 709
- Filing date
- Status date
- Registration date
- Nov 13, 2018
- Examiner
- HETZEL, DANNEAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KHPG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Sheehan Anderson
Jennifer Sheehan Anderson Bridge Intellectual Property Services143 CadyCenter, Suite 209Northville, MI 48167UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for humans for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; medicines for humans to treat or prevent diabetes, coughs, colds, influenza, headaches and allergic reactions; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations used for the relief of pain and to reduce fever; pharmaceutical preparations and substances for the prevention and/or treatment of cardiovascular diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors; contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; vitamin and mineral supplements; calcium supplements; pharmaceutical preparations, namely, ophthalmics; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; crude drugs for the treatment of central nervous system diseases, namely, hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely, dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely, wet Age-related Macular Degeneration (AMD), and other diseases, namely, fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy ; Chinese patent medicine for the treatment of central nervous system diseases, namely, hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely, dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely, wet Age-related Macular Degeneration (AMD), and other diseases, namely, fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy ; biochemical medicines for the treatment of cancer; radioactive medicines for the treatment of cancer; gases for medical purposes; disinfectants; solutions for contact lenses; dietetic substances adapted for medical use; food for babies; depuratives; pesticides; disinfectant wipes impregnated with disinfecting compounds; medical wound dressings; teeth filling materials | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks in Class 005
- Similar marks named KHPG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 14, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Sep 14, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 30, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 30, 2025 | C71T | CANCELLED SECTION 71 | — |
| Jun 9, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 13, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 10, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 10, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 10, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 10, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 10, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 10, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 19, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 21, 2019 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 21, 2019 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Feb 13, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 13, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 28, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 28, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 24, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 8, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 8, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 18, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 18, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 17, 2018 | ALIE | ASSIGNED TO LIE | — |
| Jul 5, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 9, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 9, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 19, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 18, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 12, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 7, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 23, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |